These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 20088940)

  • 1. TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain.
    Reglińska-Matveyev N; Andersson HM; Rezende SM; Dahlbäck B; Crawley JT; Lane DA; Ahnström J
    Blood; 2014 Jun; 123(25):3979-87. PubMed ID: 24740810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to activated protein C and impaired TFPI activity in women with previous hormone-induced venous thromboembolism.
    Tchaikovski SN; Thomassen MCLGD; Stickeler E; Bremme K; Rosing J
    Thromb Res; 2021 Nov; 207():143-149. PubMed ID: 34634502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.
    Dargaud Y; Wolberg AS; Gray E; Negrier C; Hemker HC;
    J Thromb Haemost; 2017 Aug; 15(8):1704-1707. PubMed ID: 28656617
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of therapeutic plasma exchange on intact protein S, apolipoproteins, and thrombin generation.
    Pitkänen HH; Haapio M; Saarela M; Taskinen MR; Brinkman HJ; Lassila R
    Transfus Apher Sci; 2024 Jun; 63(3):103918. PubMed ID: 38555232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of PROS1 mutations and clinical characteristics in three Chinese families with hereditary protein S deficiency.
    Xu F; Zhou X; Jin Y; Yang L; Pan J; Wang M; Chen X
    Ann Hematol; 2024 Feb; 103(2):653-662. PubMed ID: 38175252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case-report of the unprovoked thrombotic event in a patient with thymoma and severe FVII deficiency.
    Li L; Wu X; Wu W; Ding Q; Wang X
    Thromb J; 2023 May; 21(1):52. PubMed ID: 37143073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa.
    Maag A; van Rein N; Schuijt TJ; Kopatz WF; Kruijswijk D; Thomassen S; Hackeng TM; Camire RM; van der Poll T; Meijers JCM; Bos MHA; van 't Veer C
    J Thromb Haemost; 2022 Feb; 20(2):328-338. PubMed ID: 34773381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
    Calzavarini S; Prince-Eladnani R; Saller F; Bologna L; Burnier L; Brisset AC; Quarroz C; Reina Caro MD; Ermolayev V; Matsumura Y; Fernández JA; Hackeng TM; Griffin JH; Angelillo-Scherrer A
    Blood; 2020 May; 135(22):1969-1982. PubMed ID: 32276277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet full length TFPI-α in healthy volunteers is not affected by sex or hormonal use.
    Winckers K; Thomassen S; Ten Cate H; Hackeng TM
    PLoS One; 2017; 12(2):e0168273. PubMed ID: 28158181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.
    Ogiwara K; Nogami K; Matsumoto T; Shima M
    Int J Hematol; 2014; 99(5):577-87. PubMed ID: 24687919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of tissue factor pathway inhibitor.
    Wood JP; Ellery PE; Maroney SA; Mast AE
    Blood; 2014 May; 123(19):2934-43. PubMed ID: 24620349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue factor pathway inhibitor: structure-function.
    Broze GJ; Girard TJ
    Front Biosci (Landmark Ed); 2012 Jan; 17(1):262-80. PubMed ID: 22201743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.
    Castoldi E; Maurissen LF; Tormene D; Spiezia L; Gavasso S; Radu C; Hackeng TM; Rosing J; Simioni P
    Haematologica; 2010 Sep; 95(9):1563-71. PubMed ID: 20421270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals.
    Maurissen LF; Castoldi E; Simioni P; Rosing J; Hackeng TM
    J Thromb Haemost; 2010 Apr; 8(4):750-8. PubMed ID: 20088940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
    Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
    J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Meijers JC; Porte RJ; Lisman T
    Br J Haematol; 2013 Sep; 162(6):819-26. PubMed ID: 23841464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma.
    Castoldi E; Simioni P; Tormene D; Rosing J; Hackeng TM
    J Thromb Haemost; 2010 Feb; 8(2):294-300. PubMed ID: 20002538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein S is a cofactor for tissue factor pathway inhibitor.
    Rosing J; Maurissen LF; Tchaikovski SN; Tans G; Hackeng TM
    Thromb Res; 2008; 122 Suppl 1():S60-3. PubMed ID: 18691502
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.